View More Recent Stories
-
Guggenheim Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) Announces Health Canada Approval of DAYBUE for the Treatment of Rett Syndrome
-
Raymond James Resumes Acadia Pharmaceuticals (ACAD) at Market Perform
-
BMO Capital Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) Appoints Catherine Owen Adams as New CEO
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $28 at Needham
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at RBC Capital
-
Morgan Stanley Downgrades Acadia Pharmaceuticals (ACAD) to Equalweight
-
Acadia Pharma (ACAD) Tops Q2 EPS by 2c, provides guidance
-
Acadia Pharma (ACAD): Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating DAYBUE in Patients with Rett Syndrome Published
-
TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
BMO Capital Starts Acadia Pharmaceuticals (ACAD) at Outperform
-
Acadia Pharma (ACAD) Presents DAYBUE Real-World Evidence and Additional Data in Rett Syndrome
